Aytu Biopharma CEO granted 30,000 restricted shares

Disbrow Joshua R. reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/30/2026 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Disbrow Joshua R. reported acquisition or exercise transactions in this Form 4 filing.

Joshua R. Disbrow, chief executive officer and director of Aytu Biopharma, received a grant of 30,000 shares of restricted common stock on July 28, 2026 at $0.00 per share. One-third vests on July 28, 2027, with the rest vesting in eight equal quarterly installments beginning October 28, 2027. After this award, he directly holds 237,203 common shares.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Disbrow Joshua R.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	30,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 237,203 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

Key Figures

Restricted stock grant: 30,000 shares Grant price: 0.0000 per share Holdings after grant: 237,203 shares +2 more

5 metrics

Restricted stock grant 30,000 shares Grant of restricted common stock to CEO on July 28, 2026

Grant price 0.0000 per share Stated transaction price per share for the restricted stock award

Holdings after grant 237,203 shares Total common shares directly held by Joshua R. Disbrow after the grant

Initial vesting date July 28, 2027 Date when one-third of the restricted stock vests

Quarterly vesting installments 8 installments Equal quarterly installments beginning October 28, 2027

Key Terms

restricted stock, vest, quarterly installments

3 terms

restricted stock financial

"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

vest financial

"which vest as follows: 1/3 on July 28, 2027, with the remaining"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AYTU report for CEO Joshua R. Disbrow?

AYTU reported that CEO Joshua R. Disbrow received a grant of 30,000 shares of restricted common stock. The award was recorded at $0.00 per share and increased his direct ownership to 237,203 AYTU common shares.

How will Joshua R. Disbrow’s 30,000 AYTU restricted shares vest?

The 30,000 restricted AYTU shares granted to Joshua R. Disbrow vest over time. One-third vests on July 28, 2027, with the remaining shares vesting in eight equal quarterly installments starting on October 28, 2027.

How many AYTU shares does Joshua R. Disbrow hold after this Form 4 grant?

Following the reported grant, Joshua R. Disbrow directly holds 237,203 AYTU common shares. This total reflects the addition of 30,000 restricted shares awarded on July 28, 2026, subject to the stated vesting schedule.

Was Joshua R. Disbrow’s AYTU stock grant made under a Rule 10b5-1 plan?

The filing indicates the transaction was not made under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is marked false, meaning no such pre-arranged trading plan is associated with this award.

Did Joshua R. Disbrow buy or sell AYTU shares on the market in this Form 4?

No market purchase or sale is reported. The Form 4 shows a grant/award acquisition of 30,000 restricted AYTU shares at $0.00 per share, rather than an open-market buy or sell transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Disbrow Joshua R.

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		30,000(1)	A	$0	237,203	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

	/s/ /s/ Ryan J. Selhorn as attorney-in-fact for Joshua R. Disbrow	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)